U.S. Markets open in 8 hrs 10 mins

Infinity Pharmaceuticals, Inc. (INFI)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
1.700.00 (0.00%)
At close: 4:00PM EDT
People also watch
IRWDIMGNAEGRAVEOARRY

Infinity Pharmaceuticals, Inc.

784 Memorial Drive
Cambridge, MA 02139
United States
617-453-1000
http://www.infi.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees56

Key Executives

NameTitlePayExercisedAge
Ms. Adelene Q. PerkinsChairman and Chief Exec. Officer850.97kN/A57
Dr. Lawrence E. Bloch M.D., J.D.Pres, Principal Accounting Officer and Treasurer541.66kN/A51
Mr. Seth A. Tasker J.D.VP, Gen. Counsel & Sec.354.18kN/A38
Ms. Melissa HackelVP of Fin.N/AN/AN/A
Dr. Jeffery L. Kutok M.D., Ph.D.Chief Scientific Officer and Sr. VPN/AN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Corporate Governance

Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.